Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29249183 | 0.81 | TSHR (0.38) | MAPTTSHR | |
| SCHEMBL7189492 | 0.77 | MAPT (0.36) | MAPTALOX15TSHR | |
| SCHEMBL1537973 | 0.75 | — | — | |
| SCHEMBL8244794 | 0.75 | — | — | |
| SCHEMBL125434 | 0.75 | — | — | |
| SCHEMBL30907077 | 0.74 | MAPT (0.35) | MAPT | |
| SCHEMBL16950034 | 0.73 | — | — | |
| SCHEMBL9498558 | 0.73 | MAPT (0.38) | MAPTALOX15MEN1CYP3A4KMT2A | |
| Ammonia Solution, Strong SCHEMBL9599811 | 0.73 | MAPT (0.38) | MAPTALOX15TSHR | |
| SCHEMBL9390107 | 0.73 | MAPT (0.38) | MAPTALOX15MEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760581-B1 | RUTHENIUM COMPLEX, METHOD FOR ITS PREPARATION AND USE THEREOF | INST CHEMII ORGANICZNEJ POLSKIEJ AKADEMII NAUK (PL) | 2016-11-09 | — | — | EP | disclosed |
| US-20150298111-A1 | Ruthenium Or Osmium Complex, Method For Its Preparation And Use Thereof | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2015-10-22 | — | — | US | disclosed |
| WO-2013046108-A1 | RUTHENIUM OR OSMIUM COMPLEX, METHOD FOR ITS PREPARATION AND USE THEREOF | Instytut Chemii Organicznej Polskiej Akademii Nauk (PL) | 2013-04-04 | — | — | WO | disclosed |
| EP-0073301-B1 | PROCESS FOR THE PREPARATION OF ALPHA, BETA AND BETA, GAMMA UNSATURATED KETONES | FIRMENICH SA (CH) | 1984-11-21 | — | — | EP | disclosed |
| US-4453011-A | BASIFICATION OF A DIALLYL CARBINOL | FIRMENICH SA (CH) | 1984-06-05 | — | — | US | disclosed |
| EP-0073301-A1 | Process for the preparation of alpha, beta and beta, gamma unsaturated ketones | FIRMENICH SA (CH) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150298111-A1 | Ruthenium Or Osmium Complex, Method For Its Preparation And Use Thereof | OSTC, MRPL21, AP1M1 | MAPT 3381/4885ALOX15 2933/4885MEN1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.